Trial ChiCTR2000039462
Publication Liu J, J Infect Dis, 2021
Primary outcome on the report: 1) Neutralization antibody seroconversion and titre 28 days after the third dose; 2) RBD-IgG seroconversion 28 days after the third dose

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.